Compared with systemic chemotherapy, EGFR-TKI targeted combined chemotherapy for stage-IV lung adenocarcinoma can increase the immune function of patients, more effectively inhibit the growth and proliferation of tumor cells, and reduce the level of oxidative stress. The gene discussed is EGFR; the disease is neoplasm.